Nasdaq:US$14.76 (+0.01) | HKEX:HK$23.26 (+0.08) | AIM:£2.15 (+0.01)
搜索
新闻档案

通过选择所需的新闻类型，可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见，某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处，请以PDF版本为准。

新闻类型
公告及新闻稿
演示文稿
新闻主题
其他业务
监管通知
肿瘤学 / 免疫学
集团
12345678910
11
121314151617181920
找到相关结果： 973
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2019-08-23

和黄医药在中国启动HMPL-523治疗 免疫性血小板减少性紫癜(ITP)患者的I期临床试验
伦敦 ，2019年8月23日 (星期五)：和黄中国医药科技有限公司 (简称“和黄医药”或“Chi-Med”) (AIM/Nasdaq: HCM) 在中国启动了一项HMPL-523治疗免疫性血小板减少性紫癜(“ITP”)患者的I期临床试验。H
阅读更多
公告及新闻稿, 监管通知 | 2019-08-20

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
阅读更多
公告及新闻稿, 监管通知 | 2019-07-30

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
阅读更多
公告及新闻稿, 集团 | 2019-07-30

和黄中国医药科技公布2019年中期业绩及临床项目最新进展
伦敦：2019年7月30日(星期二): 和黄中国医药科技有限公司（Chi-Med）（AIM /纳斯达克股票代码: HCM）今天公布截至2019年6月30日的未经审核财务数据，并公布了关键临床项目的最新进展。重点包
阅读更多
公告及新闻稿, 监管通知 | 2019-07-03

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
阅读更多
公告及新闻稿, 监管通知 | 2019-07-03

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
阅读更多
公告及新闻稿, 集团 | 2019-07-03

和黄中国医药科技计划公布2019年度中期业绩（只备英文版本）
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
阅读更多
公告及新闻稿, 监管通知 | 2019-06-28

Blocklisting Six Monthly Return
London: Friday, June 28, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limite
阅读更多
公告及新闻稿, 集团 | 2019-06-28

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2019-06-27

Chi-Med Announces Secondary Offering of American Depositary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 27, 2019: Hutchison China MediTech Limited (“
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2019-06-14

和黄中国医药科技公布索凡替尼在中国以晚期非胰腺神经内分泌瘤为适应症的 III 期临床研究SANET-ep 中期分析达到主要终点并将提前终止
香港：2019 年6 月14 日，周五：和黄中国医药科技有限公司简称（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布索凡替尼以晚期非胰腺神经内分泌瘤为适应症的III
阅读更多
公告及新闻稿, 监管通知 | 2019-06-12

Block Admission Applications and Total Voting Rights
London: Wednesday, June 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordinary shares, par value
阅读更多
公告及新闻稿, 监管通知 | 2019-06-06

Disclosure Update
London: Thursday, June 6, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connec
阅读更多
演示文稿, 科学出版物 | 2019-06-01

《Clinical Cancer Research》：索凡替尼在高分化神经内分泌瘤的使用
Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao
阅读更多
公告及新闻稿, 集团 | 2019-05-29

股东特别大会结果（只备英文版本）
London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul
阅读更多
公告及新闻稿, 监管通知 | 2019-05-22

Grant of Share Options under Share Option Scheme
London: Wednesday, May 22, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
阅读更多
View Announcement (PDF)
公告及新闻稿, 集团 | 2019-05-03

股东特别大会通知及股东通函（只备英文版本）
London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An
阅读更多
公告及新闻稿, 监管通知 | 2019-04-24

股东周年大会结果（只备英文版本）
London: Wednesday, April 24, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 24, 2019 were duly
阅读更多
Download Announcement (PDF)
公告及新闻稿, 监管通知 | 2019-04-15

Disclosure Update
London: Monday, April 15, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed an application (the “Listing Application”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connection
阅读更多
Download Announcement (PDF)
公告及新闻稿, 集团 | 2019-04-15

和黄中国医药科技在香港提交上市申请并宣布拟进行全球发售
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong: Monday, April 15, 2019: Hutchison China MediTech
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2019-03-29

和黄中国医药科技在中国启动索凡替尼以不可切除或转移性胆道癌为适应症的IIb/III期临床试验
2019年3月29日，中国上海 — 和黄中国医药科技有限公司（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）在中国启动了一项有注册性潜力的IIb/III期临床试验，旨
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2019-03-28

和黄中国医药科技将于AACR年会上以口头报告形式公布沃利替尼肺癌相关项目进展
2019年3月28日，中国上海 — 和黄中国医药科技有限公司（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）将于2019年3月31日-4月3日在美国佐治亚州亚特兰大市召开的美国癌症研
阅读更多
下载通告 (PDF)
公告及新闻稿, 监管通知 | 2019-03-25

Vesting of awards under the Long Term Incentive Plan
London: Monday, March 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2018 annual report of Chi-Med on March 21 2019, the following awards granted under the Long Term Incent
阅读更多
Download Announcement (PDF)
公告及新闻稿, 集团 | 2019-03-21

2018全年财务业绩及股东周年大会通告（只备英文版本）
London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders
阅读更多
Download Announcement (PDF)
公告及新闻稿, 集团 | 2019-03-11

Publication of Form 20-F
London: Monday, March 11, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/r
阅读更多
View Form 20-F (PDF)
公告及新闻稿, 集团 | 2019-03-11

和黄中国医药科技公布2018全年财务业绩及临床项目最新进展（只备英文版本）
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas
阅读更多
Download Announcement (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2019-02-12

沃利替尼/Imfinzi®联合疗法以治疗晚期乳头状肾细胞癌为适应症的II临床研究初步数据将于2019年ASCO泌尿生殖系统肿瘤研讨会发表
香港：2019年2月12日，星期二：和黄中国医药科技有限公司 （Chi-Med）（AIM/NASDAQ: HCM）今日宣布CALYPSO II期临床研究中探索沃利替尼/Imfinzi®（durvalumab）联合疗法治疗转移性乳头状肾细胞癌（PRCC
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 集团 | 2019-02-08

和黄中国医药科技计划公布2018年度全年财务业绩（只备英文版本）
London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr
阅读更多
Download Announcement (PDF)
公告及新闻稿, 新闻稿, 集团 | 2019-01-07

和黄中国医药科技将于第37届摩根大通医疗健康年会上发表演讲（只备英文版本）
Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes
阅读更多
Download Press Release (PDF)
公告及新闻稿, 监管通知 | 2018-12-31

Blocklisting Six Monthly Return
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (
阅读更多
公告及新闻稿, 监管通知 | 2018-12-31

Total Voting Rights
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-12-20

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China –  – Chi-Med to assume all development costs of life cycle indications in
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-12-20

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy
– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China
阅读更多
公告及新闻稿, 监管通知 | 2018-12-14

TR-1: Form for notification of major holdings
公告及新闻稿, 监管通知 | 2018-11-30

Total Voting Rights
London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-11-29

和黄医药就评估索凡替尼和呋喹替尼 与 PD-1 检查点抑制剂的联合疗法签订多项合作协议
2018年11月29日，星期四：和黄中国医药科技有限公司 （简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）4项合作协议，对和黄医药的索凡替尼 （surufatinib, 亦称HMPL-012或sulfatinib
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-11-26

和黄医药宣布呋喹替尼胶囊（爱优特®）首次商业上市
2018年11月26日，星期一：和黄中国医药科技有限公司（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布呋喹替尼胶囊（爱优特®）首次商业上市，并在中国开始产品销
阅读更多
下载新闻稿 (PDF)
肿瘤学 / 免疫学 | 2018-11-20

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit
Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2018-11-16

和黄医药公布呋喹替尼在中国以三线晚期非小细胞肺癌为适应症的 III期临床试验FALUCA研究结果
- 研究没有达到总生存期的主要终点，但呋喹替尼组患者无进展生存期得到延长 -   2018年11月16日，周五：和黄中国医药科技有限公司（Chi-Med（简称“和黄医药”或 “Chi-Med”）（纳斯达
阅读更多
下载通告 (PDF)
公告及新闻稿, 监管通知 | 2018-10-31

Total Voting Rights
London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac
阅读更多
公告及新闻稿, 监管通知 | 2018-10-22

Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2018-10-18

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc
阅读更多
公告及新闻稿, 监管通知 | 2018-10-05

Appointment of HSBC Bank plc as Joint Corporate Broker in London
London: Friday, October 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will co
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2018-09-05

和黄医药宣布呋喹替尼胶囊在中国获批 用于治疗既往接受过其他治疗的结直肠癌患者
-呋喹替尼胶囊为转移性结直肠癌患者提供了新的口服治疗选择，将在中国市场以商品名爱优特®进行销售-   -已在JAMA发表的研究数据表明，和安慰剂相比爱优特®能够使患者总生存期得到
阅读更多
下载通告 (PDF)
公告及新闻稿, 监管通知 | 2018-08-31

Total Voting Rights
London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi
阅读更多
公告及新闻稿, 监管通知 | 2018-08-07

Grant of Share Options under Share Option Scheme
London: Tuesday, August 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meetin
阅读更多
公告及新闻稿, 集团 | 2018-07-27

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-07-23

和黄医药在美国启动索凡替尼以胰腺神经内分泌瘤和胆管癌为适应症的Ib/II期概念验证临床试验
2018年7月23日：和黄中国医药科技（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布在美国启动索凡替尼以胰腺神经内分泌瘤（NET）和胆管癌（BTC）为适应症的Ib/II期
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2018-06-29

Total Voting Rights
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with e
阅读更多
公告及新闻稿, 监管通知 | 2018-06-29

Blocklisting Six Monthly Return
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)
阅读更多
12345678910
11
121314151617181920